Immunobiome Begins Phase 1 Clinical Trial of Microbiome New Drug 'IMB002' in Korea
Immunobiome, an AI-based new drug development specialist company, is accelerating its microbiome drug development.
On the 29th, Immunobiome announced that it has started the domestic Phase 1 clinical trial of 'IMB002,' a candidate drug for inflammatory bowel disease (IBD) and intractable autoimmune diseases.
In this Phase 1 clinical trial, the safety, tolerability, and gut microbiome composition of IMB002 will be evaluated in Korean and Caucasian adults. After the completion of Phase 1, a proof of concept (PoC) clinical trial of IMB002 will also be conducted targeting patients with autoimmune diseases.
IMB002 is a new drug candidate discovered through Immunobiome's AI-based new drug development platform, 'Avatiom.' It induces anti-inflammatory immune responses of intestinal dendritic cells (DCs) and promotes the differentiation of regulatory T cells, thereby suppressing the production of inflammatory cytokines and enhancing the secretion of anti-inflammatory cytokines. Through preclinical studies, the company confirmed that IMB002 has therapeutic effects on inflammatory bowel disease caused by gut microbiome imbalance and intractable autoimmune diseases such as rheumatoid arthritis (RA).
A company official stated, “With the first administration of IMB002, we have officially started the domestic Phase 1 clinical trial. After completing Phase 1 within this year, we will sequentially proceed with the PoC clinical trial to accelerate microbiome drug development.”
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Meanwhile, Immunobiome is developing various microbiome therapeutics for intractable diseases using the Avatiom platform. Currently, it holds pipelines including IMB001 for atopic dermatitis treatment and IMB002 for inflammatory bowel disease and autoimmune diseases such as rheumatoid arthritis. In April, the company published a paper in the prestigious international immunology journal Nature Immunology demonstrating the immune regulatory efficacy and mechanism of action of 'IMB001,' proving its world-class technology.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
